VP1 001Alternative Names: Compound 29 - ViewPoint Therapeutics
Latest Information Update: 27 May 2016
At a glance
- Originator University of California at San Francisco; University of Michigan; University of Washington
- Class Small molecules; Sterols
- Mechanism of Action Amyloid inhibitors; Protein aggregation inhibitors; Protein folding inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cataracts
Most Recent Events
- 01 Apr 2016 ViewPoint Therapeutics receives SBIR grant from National Eye Institute for VP1 001 development in Cataracts (ViewPoint Therapeutics website)